Matches in SemOpenAlex for { <https://semopenalex.org/work/W2346514565> ?p ?o ?g. }
- W2346514565 endingPage "35" @default.
- W2346514565 startingPage "35" @default.
- W2346514565 abstract "The incorporation of various novel therapies has resulted in a significant survival benefit in newly diagnosed and relapsed patients with multiple myeloma (MM) over the past decade. Despite these advances, resistance to therapy leads to eventual relapse and fatal outcomes in the vast majority of patients. Hence, there is an unmet need for new safe and efficacious therapies for continued improvement in outcomes. Given the role of epigenetic aberrations in the pathogenesis and progression of MM and the success of histone deacetylase inhibitors (HDACi) in other malignancies, many HDACi have been tried in MM. Various preclinical studies helped us to understand the antimyeloma activity of different HDACi in MM as a single agent or in combination with conventional, novel, and immune therapies. The early clinical trials of HDACi depicted only modest single-agent activity, but recent studies have revealed encouraging clinical response rates in combination with other antimyeloma agents, especially proteasome inhibitors. This led to the approval of the combination of panobinostat and bortezomib for the treatment of relapsed/refractory MM patients with two prior lines of treatment by the US Food and Drug Administration. However, it remains yet to be defined how we can incorporate HDACi in the current therapeutic paradigms for MM that will help to achieve longer disease control and significant survival benefits. In addition, isoform-selective and/or class-selective HDAC inhibition to reduce unfavorable side effects needs further evaluation." @default.
- W2346514565 created "2016-06-24" @default.
- W2346514565 creator A5026574827 @default.
- W2346514565 creator A5074911568 @default.
- W2346514565 creator A5077401586 @default.
- W2346514565 date "2016-05-01" @default.
- W2346514565 modified "2023-09-24" @default.
- W2346514565 title "Clinical use and applications of histone deacetylase inhibitors in multiple myeloma" @default.
- W2346514565 cites W1481402708 @default.
- W2346514565 cites W1504303645 @default.
- W2346514565 cites W1516453481 @default.
- W2346514565 cites W1547154484 @default.
- W2346514565 cites W1547555729 @default.
- W2346514565 cites W1587031596 @default.
- W2346514565 cites W1840993518 @default.
- W2346514565 cites W1843609228 @default.
- W2346514565 cites W1964843472 @default.
- W2346514565 cites W1966268694 @default.
- W2346514565 cites W1973596120 @default.
- W2346514565 cites W1974991710 @default.
- W2346514565 cites W1983725816 @default.
- W2346514565 cites W1991899579 @default.
- W2346514565 cites W1992776819 @default.
- W2346514565 cites W1997961866 @default.
- W2346514565 cites W2007268478 @default.
- W2346514565 cites W2010833137 @default.
- W2346514565 cites W2011660168 @default.
- W2346514565 cites W2013320739 @default.
- W2346514565 cites W2015047229 @default.
- W2346514565 cites W2019967976 @default.
- W2346514565 cites W2020320149 @default.
- W2346514565 cites W2022811243 @default.
- W2346514565 cites W2024425375 @default.
- W2346514565 cites W2027391379 @default.
- W2346514565 cites W2029148944 @default.
- W2346514565 cites W2029598062 @default.
- W2346514565 cites W2032025341 @default.
- W2346514565 cites W2033176001 @default.
- W2346514565 cites W2033836584 @default.
- W2346514565 cites W2037841266 @default.
- W2346514565 cites W2038248421 @default.
- W2346514565 cites W2042907157 @default.
- W2346514565 cites W2043322963 @default.
- W2346514565 cites W2044098233 @default.
- W2346514565 cites W2044682579 @default.
- W2346514565 cites W2048722552 @default.
- W2346514565 cites W2052169053 @default.
- W2346514565 cites W2057551317 @default.
- W2346514565 cites W2059045913 @default.
- W2346514565 cites W2063919173 @default.
- W2346514565 cites W2064489493 @default.
- W2346514565 cites W2065327255 @default.
- W2346514565 cites W2066800926 @default.
- W2346514565 cites W2068331698 @default.
- W2346514565 cites W2077489154 @default.
- W2346514565 cites W2079167171 @default.
- W2346514565 cites W2080316252 @default.
- W2346514565 cites W2087507084 @default.
- W2346514565 cites W2088474788 @default.
- W2346514565 cites W2088587086 @default.
- W2346514565 cites W2089077371 @default.
- W2346514565 cites W2090465622 @default.
- W2346514565 cites W2092537575 @default.
- W2346514565 cites W2095026025 @default.
- W2346514565 cites W2095788199 @default.
- W2346514565 cites W2096367061 @default.
- W2346514565 cites W2097217800 @default.
- W2346514565 cites W2099262276 @default.
- W2346514565 cites W2101035019 @default.
- W2346514565 cites W2101775247 @default.
- W2346514565 cites W2104244233 @default.
- W2346514565 cites W2109118704 @default.
- W2346514565 cites W2112351720 @default.
- W2346514565 cites W2114383777 @default.
- W2346514565 cites W2117465108 @default.
- W2346514565 cites W2117551758 @default.
- W2346514565 cites W2118335184 @default.
- W2346514565 cites W2121431024 @default.
- W2346514565 cites W2125262261 @default.
- W2346514565 cites W2127009065 @default.
- W2346514565 cites W2129890171 @default.
- W2346514565 cites W2130517158 @default.
- W2346514565 cites W2132392953 @default.
- W2346514565 cites W2133024348 @default.
- W2346514565 cites W2135227533 @default.
- W2346514565 cites W2138984926 @default.
- W2346514565 cites W2139607151 @default.
- W2346514565 cites W2139849891 @default.
- W2346514565 cites W2140579395 @default.
- W2346514565 cites W2142112710 @default.
- W2346514565 cites W2142233318 @default.
- W2346514565 cites W2144991849 @default.
- W2346514565 cites W2148718757 @default.
- W2346514565 cites W2148773189 @default.
- W2346514565 cites W2149379768 @default.
- W2346514565 cites W2149386327 @default.
- W2346514565 cites W2150143712 @default.
- W2346514565 cites W2151410290 @default.